Haemonetics Corporation (HAE)

Return on assets (ROA)

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Net income (ttm)	US$ in thousands	117,558	126,574	128,277	136,566	115,401	95,759	86,047	67,706	43,375	22,593	31,243	64,488	79,469	108,134	106,147	95,532	76,526	79,737	41,363	22,603
Total assets	US$ in thousands	2,195,590	2,200,430	2,011,280	1,962,260	1,934,820	1,878,070	1,865,110	1,820,530	1,859,730	1,831,380	1,801,500	1,794,190	1,819,920	1,318,070	1,418,170	1,433,170	1,267,110	1,237,750	1,190,540	1,259,610
ROA		5.35%	5.75%	6.38%	6.96%	5.96%	5.10%	4.61%	3.72%	2.33%	1.23%	1.73%	3.59%	4.37%	8.20%	7.48%	6.67%	6.04%	6.44%	3.47%	1.79%

March 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $117,558K ÷ $2,195,590K
= 5.35%

Haemonetics Corporation's return on assets (ROA) has shown varying trends over the past few quarters. ROA is a key profitability ratio that measures a company's ability to generate earnings from its assets.

From December 2019 to September 2020, Haemonetics' ROA remained relatively stable, ranging between 3.47% and 8.20%. However, starting from June 2020, the ROA experienced a declining trend, reaching a low of 1.23% in March 2021 before gradually increasing to 6.38% by September 2023.

The increase in ROA from 3.72% in June 2022 to 6.96% in June 2023 suggests that Haemonetics improved its efficiency in generating profits from its assets during this period. The peak of 6.96% in June 2023 indicates a strong performance in utilizing the company's assets to generate earnings.

Overall, Haemonetics Corporation's ROA has shown both ups and downs over the analyzed period, reflecting fluctuations in the company's profitability and efficiency in asset utilization. It is essential for stakeholders to monitor these changes to understand the company's financial health and performance.